Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Jun Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7886-6187; OpenAlex author ID A5100433067. Sources: ClinicalTrials.gov.

Their work

Papers
15 (first author 0, last author 1)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
90
Papers, trials and grants by year

2016: 2 papers · 2017: none · 2018: 2 papers · 2019: none · 2020: 2 papers · 2021: 4 papers, 1 trial · 2022: 2 papers · 2023: 1 paper · 2024: 2 papers

Papers 15

  1. High-Intensity Focused Ultrasound Ablation Combined With Pharmacogenomic-Guided Chemotherapy for Advanced Pancreatic Cancer: Initial Experience. Co-author DOI 10.1016/j.ultrasmedbio.2024.06.013↗
  2. Efficacy of nab‑paclitaxel vs. Gemcitabine in combination with S‑1 for advanced pancreatic cancer: A multicenter phase II randomized trial. Co-author DOI 10.3892/ol.2024.14293↗
  3. The Impact of Additional Para-aortic Dissection During Pancreaticoduodenectomy for Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-12700-z↗
  4. Robotic versus open pancreaticoduodenectomy with vascular resection for pancreatic ductal adenocarcinoma: surgical and oncological outcomes from pilot experien… Co-author DOI 10.1007/s00423-021-02364-w↗
  5. Tumor microenvironmental 15-PGDH depletion promotes fibrotic tumor formation and angiogenesis in pancreatic cancer. Co-author DOI 10.1111/cas.15495↗
  6. Identification of copy number variation-driven molecular subtypes informative for prognosis and treatment in pancreatic adenocarcinoma of a Chinese cohort. Co-author DOI 10.1016/j.ebiom.2021.103716↗
  7. Preoperative plasma D-dimer independently predicts survival in patients with pancreatic ductal adenocarcinoma undergoing radical resection. Co-author DOI 10.1186/s12957-021-02281-8↗
  8. Preoperative Plasma D-Dimer Independently Predicts Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Radical Resection Co-author DOI 10.21203/rs.3.rs-308863/v1↗
  9. Immune Infiltration of CD8+ T Cells in Patients With Diabetic Pancreatic Cancer Reduces the Malignancy of Cancer Tissues: An In Silico Study. Co-author DOI 10.3389/fendo.2021.826667↗
  10. Tumor copy number instability is a significant predictor for late recurrence after radical surgery of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.3425↗
  11. Effects of high-intensity focused ultrasound treatment on peripancreatic arterial and venous blood vessels in pancreatic cancer. Co-author DOI 10.3892/ol.2020.11511↗
  12. Integrated whole genome microarray analysis and immunohistochemical assay identifies COL11A1, GJB2 and CTRL as predictive biomarkers for pancreatic cancer. Co-author DOI 10.1186/s12935-018-0669-x↗
  13. lncRNA differentiation antagonizing nonprotein coding RNA overexpression accelerates progression and indicates poor prognosis in pancreatic ductal adenocarcino… Last author DOI 10.2147/ott.s167065↗
  14. The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreati… Co-author DOI 10.3892/ijo.2015.3316↗
  15. Overexpression and biological function of IQGAP3 in human pancreatic cancer. Co-author PMID 28078013↗

Trials 1

  1. Methylene Blue and Postoperative Neurocognitive Disorders Principal investigator NCT04529265↗

Closest collaborators

The 25 strongest of 90 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiaxing Deng · 6 shared papers, 2020–2023 · strength 0.78
  2. Baiyong Shen · 5 shared papers, 2020–2023 · strength 0.64
  3. Chenghong Peng · 4 shared papers, 2020–2023 · strength 0.50
  4. Haoda Chen · 3 shared papers, 2021–2023 · strength 0.46
  5. Siyi Zou · 3 shared papers, 2021 · strength 0.38
  6. Kun Zhou · 2 shared papers, 2020–2024 · strength 0.35
  7. Chengbing Jin · 2 shared papers, 2020–2024 · strength 0.35
  8. Lifeng Ran · 2 shared papers, 2020–2024 · strength 0.35
  9. Jiabin Jin · 3 shared papers, 2020–2022 · strength 0.32
  10. Yuanchi Weng · 2 shared papers, 2022–2023 · strength 0.31
  11. Xing Chen · 1 shared paper, 2024 · strength 0.24
  12. Liang Liu · 2 shared papers, 2016–2024 · strength 0.20
  13. Deliang Fu · 2 shared papers, 2016–2024 · strength 0.20
  14. Dongfeng Cheng · 2 shared papers, 2020–2021 · strength 0.18
  15. Qian Zhan · 2 shared papers, 2020–2021 · strength 0.18
  16. Jiancheng Wang · 2 shared papers, 2020–2021 · strength 0.18
  17. Chenlei Wen · 2 shared papers, 2020–2021 · strength 0.18
  18. Hao Chen · 2 shared papers, 2020–2021 · strength 0.18
  19. Ziyun Shen · 1 shared paper, 2023 · strength 0.17
  20. Yuchen Ji · 1 shared paper, 2023 · strength 0.17
  21. Yiran Zhou · 1 shared paper, 2023 · strength 0.17
  22. Weishen Wang · 1 shared paper, 2023 · strength 0.17
  23. Lie Yao · 1 shared paper, 2024 · strength 0.16
  24. Xuefeng Xu · 1 shared paper, 2024 · strength 0.16
  25. Yaolin Xu · 1 shared paper, 2024 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.